HIV/AIDS Medications: Research on Isentress
- ICAAC 2007 Study Summaries: An Interview With Joseph Eron, M.D. (September 20, 2007)
Dr. Eron discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced HIVers.
From TheBodyPRO.com
- Briefing Document (Background Package): Raltegravir (PDF) (September 5, 2007)
FDA Antiviral Drugs Advisory Committee Meeting.
From U.S. Food and Drug Administration
- Faster Viral Decay With Raltegravir (July 24, 2007)
Treatment with raltegravir (RAL, MK-0518) produces more rapid viral load reductions than efavirenz (EFV, Sustiva, Stocrin) and significantly reduced the magnitude of the second phase of viral decay. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
- Cross-Resistance Between Integrase Inhibitors (July 24, 2007)
It appears that virologic failure with one of the current integrase inhibitors is likely to severely limit subsequent treatment options within that class according to a small cohort study. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
- FDA Grants Speedy Review for First HIV Integrase Inhibitor (June 29, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- 77% of Treatment-Experienced Patients on MK-0518 (raltegravir) Plus OBT Achieve Viral Load of Less Than 400 Copies: A Study Summary From David Cooper, M.D., and Roy Steigbigel, Ph.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- 79% of Treatment-Experienced Patients on MK-0518 Plus OBT Achieve Viral Load of Less Than 400 Copies at Week 16 (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- The Next HIV Therapies (February 2007)
MK-0518, TMC125 and Maraviroc.
In HIV JournalView, from TheBodyPRO.com
- New Experimental Drug Integrase Inhibitor (MK-0518) (October/November 2006)
In Survival News, from AIDS Survival Project
- MK-0518 Demonstrates Potent Efficacy in Patients With Triple-Class-Resistant Virus: 24-Week Results (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- The Integrase Inhibitor MK-0518 Demonstrates a Favorable Lipid Profile (September 27, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Potent Antiretroviral Effect Seen With the Integrase Inhibitor MK-0518 as Part of Combination ART in Treatment-Naive, HIV-1-Infected Patients (August 17, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- EARMRK: Expanded Access Research Program for MK-0518 (PDF) (August 17, 2006)
From Merck & Co., Inc.
- Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options (August 17, 2006)
Worldwide access program will be conducted along with phase III studies.
To read PDF, click here.
From Merck & Co., Inc.
On TheBodyPRO.com
- Integrase Inhibitors: The Next Wave? (Spring 2006)
A quick look at MK-518 and GS-9137.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
On TheBodyPRO.com
- Integrase Inhibitors (February 25, 2005)
To read PDF, click here.
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
